rs563345694
Variant summary
Our verdict is Likely benign. Variant got -4 ACMG points: 1P and 5B. PP2BP6BS2
The NM_001127222.2(CACNA1A):c.6125C>T(p.Thr2042Met) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000639 in 1,610,832 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Synonymous variant affecting the same amino acid position (i.e. T2042T) has been classified as Benign.
Frequency
Consequence
NM_001127222.2 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -4 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CACNA1A | NM_001127222.2 | c.6125C>T | p.Thr2042Met | missense_variant | 42/47 | ENST00000360228.11 | NP_001120694.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
CACNA1A | ENST00000360228.11 | c.6125C>T | p.Thr2042Met | missense_variant | 42/47 | 1 | NM_001127222.2 | ENSP00000353362.5 | ||
CACNA1A | ENST00000638029.1 | c.6143C>T | p.Thr2048Met | missense_variant | 43/48 | 5 | ENSP00000489829.1 | |||
CACNA1A | ENST00000573710.7 | c.6131C>T | p.Thr2044Met | missense_variant | 42/47 | 5 | ENSP00000460092.3 | |||
CACNA1A | ENST00000635727.1 | c.6128C>T | p.Thr2043Met | missense_variant | 42/47 | 5 | ENSP00000490001.1 | |||
CACNA1A | ENST00000637769.1 | c.6128C>T | p.Thr2043Met | missense_variant | 42/47 | 1 | ENSP00000489778.1 | |||
CACNA1A | ENST00000636012.1 | c.6128C>T | p.Thr2043Met | missense_variant | 42/46 | 5 | ENSP00000490223.1 | |||
CACNA1A | ENST00000637736.1 | c.5987C>T | p.Thr1996Met | missense_variant | 41/46 | 5 | ENSP00000489861.1 | |||
CACNA1A | ENST00000636389.1 | c.6128C>T | p.Thr2043Met | missense_variant | 42/47 | 5 | ENSP00000489992.1 | |||
CACNA1A | ENST00000637432.1 | c.6143C>T | p.Thr2048Met | missense_variant | 43/48 | 5 | ENSP00000490617.1 | |||
CACNA1A | ENST00000636549.1 | c.6134C>T | p.Thr2045Met | missense_variant | 43/48 | 5 | ENSP00000490578.1 | |||
CACNA1A | ENST00000637927.1 | c.6131C>T | p.Thr2044Met | missense_variant | 42/47 | 5 | ENSP00000489715.1 | |||
CACNA1A | ENST00000635895.1 | c.6128C>T | p.Thr2043Met | missense_variant | 42/47 | 5 | ENSP00000490323.1 | |||
CACNA1A | ENST00000638009.2 | c.6128C>T | p.Thr2043Met | missense_variant | 42/47 | 1 | ENSP00000489913.1 | |||
CACNA1A | ENST00000637276.1 | c.6128C>T | p.Thr2043Met | missense_variant | 42/46 | 5 | ENSP00000489777.1 | |||
CACNA1A | ENST00000636768.1 | n.*427C>T | non_coding_transcript_exon_variant | 7/10 | 5 | ENSP00000490190.2 | ||||
CACNA1A | ENST00000636768.1 | n.*427C>T | 3_prime_UTR_variant | 7/10 | 5 | ENSP00000490190.2 |
Frequencies
GnomAD3 genomes AF: 0.0000526 AC: 8AN: 152144Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000374 AC: 9AN: 240506Hom.: 0 AF XY: 0.0000460 AC XY: 6AN XY: 130564
GnomAD4 exome AF: 0.0000651 AC: 95AN: 1458688Hom.: 0 Cov.: 34 AF XY: 0.0000607 AC XY: 44AN XY: 725350
GnomAD4 genome AF: 0.0000526 AC: 8AN: 152144Hom.: 0 Cov.: 32 AF XY: 0.0000538 AC XY: 4AN XY: 74308
ClinVar
Submissions by phenotype
not provided Uncertain:2Benign:1
Likely benign, criteria provided, single submitter | clinical testing | GeneDx | Jun 18, 2021 | In silico analysis, which includes protein predictors and evolutionary conservation, supports a deleterious effect; Has not been previously published as pathogenic or benign to our knowledge; This variant is associated with the following publications: (PMID: 30755392) - |
Uncertain significance, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Jun 01, 2018 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Athena Diagnostics | Aug 27, 2018 | - - |
Neurogenic bladder;C0026826:Hypertonia;C0026838:Spasticity;C0026975:Myelitis;C0151786:Muscle weakness;C0151945:Cerebral venous thrombosis;C0231687:Spastic gait;C0948163:Abnormal cerebral white matter morphology;C1855710:Bone marrow hypocellularity;C2711630:Combined immunodeficiency;C4022749:Abnormal brainstem MRI signal intensity;C4022770:Abnormal thalamic MRI signal intensity Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Center for Personalized Medicine, Children's Hospital Los Angeles | - | - - |
CACNA1A-related disorder Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | PreventionGenetics, part of Exact Sciences | Dec 28, 2022 | The CACNA1A c.6125C>T variant is predicted to result in the amino acid substitution p.Thr2042Met. This variant was reported in an individual with cerebral white matter abnormalities, cerebral venous thrombosis, myelitis, immunodeficiency, and spasticity (referred to as c.6128C>T, p.Thr2043Met in Supplemental Table 2, Ji et al. 2019. PubMed ID: 30755392). This variant is reported in 0.0058% of alleles in individuals of Latino descent in gnomAD (http://gnomad.broadinstitute.org/variant/19-13323262-G-A). At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. - |
Spinocerebellar ataxia type 6;C1720416:Episodic ataxia type 2;C1832884:Migraine, familial hemiplegic, 1;C4310716:Developmental and epileptic encephalopathy, 42 Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Oct 31, 2018 | - - |
Episodic ataxia type 2;C4310716:Developmental and epileptic encephalopathy, 42 Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 04, 2024 | - - |
Inborn genetic diseases Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Ambry Genetics | Jan 17, 2019 | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at